Xanthine Oxidase Inhibition in Renal Transplant Recipients

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Complications of Renal Transplant

In brief

Cardiovascular disease is the leading cause of mortality in kidney transplantation. The enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health and protects against cardiovascular complications.

Key facts

Study ID

NCT01332799

Run by

Roberto S Kalil

People needed

20

Starts

2011-02-01

Expected to finish

2018-08-10

Last updated by the study team

2019-10-15

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• age 18 years or older
• both genders
• recipients of living donor or deceased-donor kidney transplant with stable renal function

You may not qualify if…

• history of gout
• allergy to allopurinol
• use of azathioprine

Where it is running

• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.